Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:08329's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.06 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Shenzhen Neptunus Interlong Bio-Technique Co Forward Dividend Yield % Related Terms
HKSE:08329 vs ZTS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Neptunus Interlong Bio-Technique Co Forward Dividend Yield % vs Drug Manufacturers Industry
What does a Forward Dividend Yield % of 0.00% mean?
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a Forward Dividend Yield % of 0.00% as of Sep. 15, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. According to the industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #999999 out of 503 companies in the Drug Manufacturers industry.
Is Shenzhen Neptunus Interlong Bio-Technique Co's Forward Dividend Yield % too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #999999 out of 503 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shenzhen Neptunus Interlong Bio-Technique Co has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Neptunus Interlong Bio-Technique Co's Forward Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #999999 out of 503 companies for Forward Dividend Yield %. This places Shenzhen Neptunus Interlong Bio-Technique Co in the lower half of its industry. The industry median Forward Dividend Yield % is 2.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.06, based on 503 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Neptunus Interlong Bio-Technique Co's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.10 — trading 29.3% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Shenzhen Neptunus Interlong Bio-Technique Co's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current Forward Dividend Yield % is 0.00% as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co stock appears to be undervalued.
The current stock price of HK$0.10 is trading 29.3% below its estimated GF Value™ of HK$0.14.
GuruFocus considers Shenzhen Neptunus Interlong Bio-Technique Co to be Modestly Undervalued.
Key valuation signals for HKSE:08329:
Forward Dividend Yield %: 0.00%
GF Value™: HK$0.14 vs. price of HK$0.10 (29.3% below fair value)
No single metric tells the full story. See the HKSE:08329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
48GF Score
Get the complete analysis for HKSE:08329
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08329 has been successfully added to your 
